Innovent Biologics Inc. has received regulatory approval from China's National Medical Products Administration (NMPA) for PECONDLE® (picankibart injection), a recombinant anti-interleukin-23p19 subunit antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy. This approval marks PECONDLE® as the first domestically developed IL-23p19 inhibitor in China for this indication. The approval was based on positive results from a Phase 3 registrational study, where the drug demonstrated significant improvement in clinical endpoints compared to placebo.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251128-11931888), on November 28, 2025, and is solely responsible for the information contained therein.